8-K current report · filed Sep 3, 2026

Teva Pharmaceutical Industries Ltd (TEVA) 8-K Current Report: September 3, 2026

Item 8.01Item EX-99.1TEVA overview

Short answer

Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Teva reclassified Anda, its U.S. distribution business, from the United States segment to Other Activities effective January 1, 2026.

Teva Pharmaceutical Industries Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Teva reclassified Anda, its U.S. distribution business, from the United States segment to Other Activities effective January 1, 2026
  • Segment disclosures in the 2025 Form 10-K were recast to align with Teva’s Pivot to Growth strategy and internal reporting
  • Consolidated balance sheets, income statements, cash flows and equity statements remain unchanged
  • Recast data affects reported segment revenue, profitability and reconciliations, requiring revised comparisons across periods
  • Exhibit 99.1 updates business, MD&A and segment-note disclosures for investor analysis

Item EX-99.1 · Exhibit EX-99.1

  • Historical segment reporting recast effective January 1, 2026, moving U.S. distribution business Anda into Other Activities
  • United States segment now excludes Anda, sharpening visibility into regional pharmaceutical performance and biopharmaceutical growth engines
  • Filing is not a financial restatement, with no changes to consolidated balance sheets, income statements or cash flows
  • Investors should adjust historical segment comparisons and review 2026 Form 10-Q disclosures for comparability

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Teva Pharmaceutical Industries Ltd 8-K filings

Get the next TEVA 8-K as it lands

Follow TEVA for push alerts, or ask the research agent what this filing means.